| Net loss | -19.43M |
| Depreciation | 9.93K |
| Amortization of patents | |
| Amortization of original issue discount | |
| Amortization of commitment fee | |
| Amortization of prepaid consultant expense | |
| Amortization of deferred loan costs | |
| Accretion of United States Treasury Bills | |
| Loss on extinguishment of debt | |
| Loss on exercise of warrants | |
| Beneficial conversion of convertible interest | |
| Convertible interest | |
| Compensation through issuance of stock options | |
| Compensation through issuance of stock | |
| Issuance of stock for services | 20.16K |
| Issuance of warrants for services | |
| Issuance of warrants for contractual obligations | |
| Gain on sale of equipment | |
| Gain on change in fair value of warrant liability | |
| Prepaid expenses and other current assets | |
| Accounts payable | -400.93K |
| Accrued expenses | 161.53K |
| Net cash used in operating activities | |
| Proceeds from sale of fixed assets | |
| Capital expenditures | 0 |
| Proceeds from sales of investments | |
| Purchases of investments | |
| Net cash (used in) provided by investing activities | |
| Net proceeds from loans from stockholder | |
| Proceeds from convertible debt | |
| Net proceeds from sales of preferred stock and warrants | |
| Net proceeds from sales of common stock and warrants | 0 |
| Proceeds from exercises of warrants and stock options | 0 |
| Cash paid to retire convertible debt | |
| Cash paid for deferred loan costs | |
| Premium paid on extinguishments of debt | |
| Purchase and retirement of common stock | |
| Net cash provided by financing activities | |
| Net change in cash and cash equivalents | -9M |
| Cash and cash equivalents, at beginning of period | 14.18M |
| Cash and cash equivalents, at end of period | 5.18M |
| Amount Reclassified From Warrant Liability To Equity | |